Member Info for RiskIsReward

Yes, I'm very serious. Only wife* had some mild symptoms. I never said Covid is over, i just said it is pretty much under control.

All this new variants of Covid on news and people are talking about are milder than flu. All of our family had it last week afte attending a wedding., myself and kids had absolute no symptoms and complete fine. My was showed mild symptoms of cold and cough. So i beleive Covid is pretty much under control.
Anyways govt already caused massive dent to economy with lock downs and public hug spending and it dont think they can do it again. Market is very saturated and do not anticipate big money from covid products.

AIHL rollout for NHS is a 2023/2024 play from looks of the NICE timelines to include it in guidance.

The only catalyst for company is to complete the AIHL pilot study in greece and launch in Europe, hope there are no hurdles like NICE over there.

Wait for full year resutlts and cash balance could be vital if things are running so late.

Just presented what was in RNS, it is factual information and i was talking about near term profit which is 2023. Anyways this is just my opinion and no way talking down the SP.
I would wait till the full year results are out.

The company would post loss this year too, but its important to know cash at Bank and details f funds required to scale up productions and other costs.

Due to the disruption and the forecast of a further storm in the coming week, the Company's expected flake graphite production for the second half of the financial year to 31 March 2022 has been revised from c.4,000 tons to between 3,200-3,500 tons (FY2021: 1,718 tons). The Company continues to anticipate strong production growth thereafter with its forecast production for the financial year to 31 March 2023 remaining unchanged at c.20,000 tons.

Gross profit per MT is 321 = That makes a total profit of 20000 x 3210 = 6.42m, That would yeald a healthy profit of 5m less operational expenses at the end of FY2023. Conseravative income mutiple of 10 makes it 50m, Even at this price the current SP has priced in future already.

check comments on social media, exlains the the current state of the company.
https://twitter.com/genedriveplc/status/1537349565103452160

NICE process indeed slow, This is exactly what I was fearing.. I doubt any AIHL sales this year

8 months gone by since last fund raise.. we probably had spent half of the money already by now and still no signs of sales. We need good 10m revenue assuming we operate at 50% margin to break even.
Things are not looking good. Wait for full years results in december.

This is not going anywhere unless sales are announced. AIHL is a 2023/2024 thing, how are we going get revenue this year?

This is not first time Budd went to silent mode. After literally delayed every single product launch and failed to materialise sales. The investors still believe in Budd and giving him one more chance to turn things around.

now tell me who got to balme?

During last fund raise, only 4,450,852 Shares were subscribed by PI's in Open Offer from the total of 18,091,442 available.
Just 25% take up which explains the anger.
Secondly 24,000,000 Placing Shares were issued equivalent to 25.8%,but no single TR1. He clearly sold them to a syndicate.

When company releases sales/revenue news the sp would rerate anyways, so if you believe in the company sit tight and hold.

You have to wait for full year results and presntation for any fruther update until then the speculation (ramping/deramping) continues.

I'm afraid to say things are not looking good for GDR with no sales annoucned from POC and AIHL. we are already 8 months down since last round of fund raise. we need significant sales not just some sales.
And the Budd silence continues...

Last time i bought was before the fund raise at covid time and made a healthy profit. This is once again coming into buy zone. But only one thing concerns me from full year results:
Revenue was £375.1m for the year (FY21: £397.4m) - revunue down
Operating profit of £36.4m (FY21: £38.1m) - profit down
Strong operating cash flow generation of £18.3m (FY21: £5.6m net outflow)
but the net Debt concerns me, which went up by 36.5% from 52.3m to 71.4m
Keeping an eye on this for now.

Genedrive is very slow in getting their products to market.
PCR test submitted so late and never recived FDA as we were so far behind the queue.
Same is case with POC, it was pushed to back burner for almost 12 months. Again late to market.
Both gold standard products but unfortunately no sales. So timing is important along with quality.
Lucky AIHL has no competition otherwise with Budd's speed we would have lost this too.

Along with quality of product timing is also important.

AIHL would be really slow and might take another 18 months for full NHS adoption in UK.
The company do need sales from POC which i doubt or may be AIHL EU sale (Greece pilot study needs to completed quickly to comence sales in EU)

Todays RNS can only be seen as positive as there are no more applications pending from regulatory authorities. genedrive can now solely focus on sales and future product development.

"Between 8 October 2019 and 14 January 2021, 1410 OAT clients attended the 40 pharmacies that were participating in the trial."

Looks like and old study which just got published now.

great find Jay.
But This looks like another Beckman deal where they want to sell own their kits to go with Genedrive POC. This means nothing unless some confirmed sales are announced
https://mirnaxbiosens.com/productos/kits

Features wise covid POC which was built on Genedrive instrument version 1 lacks intergration into NHS software and printer functions. Unless the company updates the test to run on the newer instrument i dont think NHS would show any interest.
That would mean more time and money, and queing for approval from start again.